KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $114000.0.

  • Nektar Therapeutics' Capital Expenditures fell 8288.29% to $114000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $612000.0, marking a year-over-year decrease of 5088.28%. This contributed to the annual value of $1.5 million for FY2024, which is 6971.1% up from last year.
  • Nektar Therapeutics' Capital Expenditures amounted to $114000.0 in Q3 2025, which was down 8288.29% from $37000.0 recorded in Q2 2025.
  • In the past 5 years, Nektar Therapeutics' Capital Expenditures registered a high of $5.9 million during Q4 2021, and its lowest value of $2000.0 during Q1 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $433000.0 (2023), whereas its average is $1.2 million.
  • As far as peak fluctuations go, Nektar Therapeutics' Capital Expenditures soared by 191818.18% in 2024, and later crashed by 9872.61% in 2025.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Capital Expenditures stood at $5.9 million in 2021, then tumbled by 91.32% to $512000.0 in 2022, then plummeted by 53.71% to $237000.0 in 2023, then surged by 93.67% to $459000.0 in 2024, then plummeted by 75.16% to $114000.0 in 2025.
  • Its Capital Expenditures was $114000.0 in Q3 2025, compared to $37000.0 in Q2 2025 and $2000.0 in Q1 2025.